SCHEMBL23934136

SCHEMBL23934136

CCCC(C)(C)Oc1cccc(SC)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
RAB9A P51151 2/20 0.35
LMNA P02545 2/20 0.35
NPC1 O15118 1/20 0.35
PPARG P37231 2/20 0.34
PPARA Q07869 2/20 0.34
GAA P10253 1/20 0.34
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KIF11 P52732 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
DRD2 P14416 1/20 0.33
DRD1 P21728 1/20 0.33
DRD4 P21917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11659680 0.84 PPARA (0.39) KMT2APPARGPPARATP53TSHR
SCHEMBL21232627 0.79 KIF11 (0.39) ALDH1A1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL23934134 0.78 CNR1 (0.43) ALDH1A1SMN1; SMN2LMNATSHRDRD2
SCHEMBL19387702 0.77 KMT2A (0.45) MEN1KMT2ASMN1; SMN2LMNAPKM
SCHEMBL11620191 0.77 MAOB (0.37) PPARGPPARA
SCHEMBL15356133 0.75 NPC1 (0.40) SMN1; SMN2RAB9ALMNANPC1PPARG
SCHEMBL1452863 0.75 LTA4H (0.39) PPARGPPARATSHRNPSR1
SCHEMBL21116322 0.75 KIF11 (0.45) MEN1KMT2ASMN1; SMN2TP53KIF11
SCHEMBL19185668 0.74 L3MBTL1 (0.48) ALDH1A1LMNAPPARGPPARAPKM
SCHEMBL2495150 0.74 NOTUM (0.42) ALDH1A1HPGDSMN1; SMN2RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312511-A1 SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2023-10-05 US disclosed
US-20210323941-A1 SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE THE UNIVERSITY OF KANSAS 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323941-A1 SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE SLC6A3, DRD3, CHRM2 ALDH1A1 2789/4885HPGD 3694/4885MEN1 3264/4885
US-20230312511-A1 SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE SLC6A3, DRD3, DRD2 ALDH1A1 2379/4885HPGD 3456/4885MEN1 3373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.